Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Primary Prevention of Skin Dysplasia in Renal Transplant Recipients With Photodynamic Therapy: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A K Andreassen
  • Birgitta Pernilla Andersson
  • F Gustafsson
  • H Eiskjaer
  • G Radegran
  • E Gude
  • K Jansson
  • D Solbu
  • V Sigurdardottir
  • S Arora
  • G Dellgren
  • L Gullestad
  • SCHEDULE Investigators
View graph of relations

In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart transplant recipients. Patients were assigned within 5 days posttransplant to low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n = 56), or standard-exposure cyclosporine (n = 59), with both mycophenolate mofetil and corticosteroids. In the everolimus group, cyclosporine was withdrawn after 7–11 weeks and everolimus exposure increased (6–10 ng/mL). The primary efficacy end point, measured GFR at 12 months posttransplant, was significantly higher with everolimus versus cyclosporine (mean ± SD: 79.8 ± 17.7 mL/min/1.73 m2 vs. 61.5 ± 19.6 mL/min/1.73 m2; p < 0.001). Coronary intravascular ultrasound showed that the mean increase in maximal intimal thickness was smaller (0.03 mm [95% CI 0.01, 0.05 mm] vs. 0.08 mm [95% CI 0.05, 0.12 mm], p = 0.03), and the incidence of cardiac allograft vasculopathy (CAV) was lower (50.0% vs. 64.6%, p = 0.003), with everolimus versus cyclosporine at month 12. Biopsy-proven acute rejection after weeks 7–11 was more frequent with everolimus (p = 0.03). Left ventricular function was not inferior with everolimus versus cyclosporine. Cytomegalovirus infection was less common with everolimus (5.4% vs. 30.5%, p < 0.001); the incidence of bacterial infection was similar. In conclusion, everolimus-based immunosuppression with early elimination of cyclosporine markedly improved renal function after heart transplantation. Since postoperative safety was not jeopardized and development of CAV was attenuated, this strategy may benefit long-term outcome.

Original languageEnglish
JournalAmerican Journal of Transplantation (Online)
Volume14
Issue number8
Pages (from-to)1828-38
Number of pages11
ISSN1600-6143
DOIs
Publication statusPublished - Aug 2014

ID: 45026590